GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » 3-Year FCF Growth Rate

Cosmo Pharmaceuticals NV (XSWX:COPN) 3-Year FCF Growth Rate : 0.00% (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV 3-Year FCF Growth Rate?

Cosmo Pharmaceuticals NV's Free Cash Flow per Share for the six months ended in Jun. 2023 was CHF0.49.

During the past 12 months, Cosmo Pharmaceuticals NV's average Free Cash Flow per Share Growth Rate was 183.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Cosmo Pharmaceuticals NV was 143.30% per year. The lowest was -19.10% per year. And the median was 26.60% per year.


Competitive Comparison of Cosmo Pharmaceuticals NV's 3-Year FCF Growth Rate

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's 3-Year FCF Growth Rate falls into.



Cosmo Pharmaceuticals NV 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Cosmo Pharmaceuticals NV  (XSWX:COPN) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Cosmo Pharmaceuticals NV 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines